SyMap has completed enrollment for a trial looking at using targeted renal denervation to treat uncontrolled hypertension.

The Suzhou, China-based company said the SMART Study is a prospective, multicenter, single-blind, randomized, and sham-controlled trial to evaluate the safety and efficacy of targeted renal sympathetic denervation using SyMapCath I and SymPioneer in patients with essential hypertension for at least six months of the disease history and pharmacotherapy.

The study enrolled a total of 220 patients at 16 hospitals in China with dual primary endpoints: the control rate of office systolic blood pressure at six months (SBP<140 mmHg); the change in composite index based on the classes and doses of antihypertensive drugs to reach the control of office systolic blood pressure (<140 mmHg) at six months.  

SyMap said the system is able to map renal nerves and provide real time feedback before, during, and after RDN procedure in order to achieve selective ablation of renal sympathetic nerves. The completion of enrollment is a major milestone in bringing SyMap's renal nerve mapping/selective ablation system to clinical practice for treatment of uncontrolled hypertension.